Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.

By D. Berthold, G. Pond, F. Soban, R. de Wit, M. Eisenberger, I. Tannock. Journal of Clinical Oncology, 2008

1,169 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/a0e9df9ab747cb7ed4bbc6ac457cf62082beff5a